A phase Ib trial of an anti-idiotypic vaccine for Lewis Y (IGN 301) administered subcutaneously in patients with refractory solid tumors
| Autor: | P. Heeger, M. Roddy, Hans Loibner, Paul Elson, Snehal G. Thakkar, G. Himmler, B. Wacker, G. Waxenecker, Ronald M. Bukowski |
|---|---|
| Rok vydání: | 2004 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 22:2586-2586 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2004.22.90140.2586 |
| Popis: | 2586 Background: The Lewis Y (LeY) antigen is expressed on 60–90% of solid tumors with limited expression on normal tissue. This property has attracted interest to use LeY antigen as a vaccine in cancer immunotherapy. Use of an anti-idiotypic antibody (IGN 301) as an immunogenic surrogate for the LeY antigen is hypothesized to elicit a strong IgG response. We are conducting a phase I trial of IGN 301 to determine the safety, immunologic effects and antitumor activity with and without GM-CSF or IFN-α2b. Methods: Twenty-eight patients with solid tumor refractory to standard therapy enrolled in 2 cohorts. Cohort 1 received vaccine alone and cohort 2 received vaccine plus colony stimulating factor (GM-CSF). The immunogenicity of IGN 301 was assessed by measurement of the total humoral immune response. Seroconversion was assayed by ELISA and defined as a serum Ig titer of at least 1:100 against the murine type anti-idiotypic antibody used as vaccine antigen in IGN 301. T-cell reactivity was assessed by ELISPOT... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|